We are developing an enzyme inhibitor with pico-‐molar binding affinity and minimal toxicity as a once daily, oral therapeutic for the treatment of triple-‐negative breast cancer.
For more information about how to join us please contact Executive Director, Mary Howard at Mary@FirstXFounder.com
For more information about how to join us please contact Executive Director, Mary Howard at Mary@FirstXFounder.com
Employees: 11-50
Founded date: 2008